欢迎访问西亚试剂!
西亚试剂banner
西亚试剂banner
西亚试剂banner

当前位置:首页 > 新闻中心

西亚试剂:Epigenetic-Mediated Dysfunction of the Bone Morphogenetic P

发布时间:2025-10-08

Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells

Jeongwu Lee,1 Myung Jin Son,1 Kevin Woolard,1 Nicholas M. Donin,1 Aiguo Li,1 Chui H. Cheng,1 Svetlana Kotliarova,1 Yuri Kotliarov,1 Jennifer Walling,1 Susie Ahn,1 Misuk Kim,1 Mariam Totonchy,1 Thomas Cusack,1 Chibawanye Ene,1 Hilary Ma,1 Qin Su,1 Jean Claude Zenklusen,1 Wei Zhang,1 Dragan Maric,1 and Howard A. Fine1,

1 Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892, USA

Corresponding author
Howard A. Fine
hfine@mail.nih.gov

Despite similarities between tumor-initiating cells with stem-like properties (TICs) and normal neural stem cells, we hypothesized that there may be differences in their differentiation potentials. We now demonstrate that both bone morphogenetic protein (BMP)-mediated and ciliary neurotrophic factor (CNTF)-mediated Jak/STAT-dependent astroglial differentiation is impaired due to EZH2-dependent epigenetic silencing of BMP receptor 1B (BMPR1B) in a subset of glioblastoma TICs. Forced expression of BMPR1B either by transgene expression or demethylation of the promoter restores their differentiation capabilities and induces loss of their tumorigenicity. We propose that deregulation of the BMP developmental pathway in a subset of glioblastoma TICs contributes to their tumorigenicity both by desensitizing TICs to normal differentiation cues and by converting otherwise cytostatic signals to proproliferative signals.

 

上一篇:西亚试剂:菲
下一篇:西亚试剂:2-羟基喹啉
版权所有:山东西亚化学有限公司

鲁ICP备20015914号-4